Design Considerations of Scaffold-Based Systems for Controlled Drug Delivery
Year: 2026
Type: article
Abstract: Scaffold-based drug-delivery systems integrate structural support with localized therapeutic delivery, offering versatile platforms for tissue regeneration and disease management. This review examines biomaterial selection, scaffold architectures, fabrication strategies, evaluation methods, release kinetics, therapeutic applications, and barriers to clinical translation. Natural and synthetic polymers, copolymers, bioceramics, and biocomposites are discussed in relation to biocompatibility, mechanical performance, degradation, and drug-loading requirements. Particular emphasis is placed on the relationships between scaffold composition, architecture, and drug-release behavior across hydrogels, microparticles, membranes, nanofibers, and three-dimensional printed systems. Conventional fabrication approaches and advanced manufacturing technologies, including electrospinning, three-dimensional printing, and bioprinting, enable modulation of porosity, geometry, and drug distribution. Core–shell, multilayer, crosslinked, and nanoparticle-loaded architectures can mitigate burst release and facilitate sustained, sequential, or stimuli-responsive delivery. Physicochemical characterization, kinetic modeling, and biological evaluation are considered essential for linking material properties with release mechanisms, cellular responses, and safety. Therapeutic applications encompass bone and cartilage regeneration, wound healing, cancer treatment, neural repair, and ocular delivery. Despite promising experimental developments, translation remains constrained by material variability, manufacturing reproducibility, scale-up difficulties, sterilization effects, insufficiently standardized testing, uncertain in vitro–in vivo correlations, and regulatory complexity. Emerging directions include nanotechnology-enabled scaffolds, responsive materials, four-dimensional printing, computational optimization, and patient-specific designs. Future progress requires quality-by-design approaches, standardized natural and herbal components, validated analytical methods, biorelevant release testing, and long-term safety assessment. Aligning scaffold innovation with scalable manufacturing and clinically relevant therapeutic outcomes will be essential to advance these multifunctional platforms toward reproducible, safe, and effective clinical applications across tissue-specific therapeutic and regenerative settings. Keywords Scaffold-based drug delivery; Tissue engineering; Controlled release; Biomaterials; Electrospinning; Three-dimensional printing.
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Keywords: controlled drug release, tissue engineering scaffolds, biomaterials, electrospinning, three-dimensional printing, bioprinting, hydrogels, nanofibers, bioceramics, biocomposites, drug release kinetics, stimuli-responsive delivery, wound healing, cancer therapy, neural repair, ocular drug delivery, quality by design, clinical translation barriers
Open Access status: green
OpenAlex ID: W7236716132
